471 related articles for article (PubMed ID: 24485523)
1. Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
Perez-Gracia JL; Labiano S; Rodriguez-Ruiz ME; Sanmamed MF; Melero I
Curr Opin Immunol; 2014 Apr; 27():89-97. PubMed ID: 24485523
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
3. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
Brunner-Weinzierl MC; Rudd CE
Front Immunol; 2018; 9():2737. PubMed ID: 30542345
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
5. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
9. [Anti-PD-1 antibody: basics and clinical application].
Tanaka Y; Okamura H
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
[TBL] [Abstract][Full Text] [Related]
10. [Immune-checkpoints: the new anti-cancer immunotherapies].
Ileana E; Champiat S; Soria JC
Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
12. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
13. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
Intlekofer AM; Thompson CB
J Leukoc Biol; 2013 Jul; 94(1):25-39. PubMed ID: 23625198
[TBL] [Abstract][Full Text] [Related]
14. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
16. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
[TBL] [Abstract][Full Text] [Related]
17. Targeting T Cell Co-receptors for Cancer Therapy.
Callahan MK; Postow MA; Wolchok JD
Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
[TBL] [Abstract][Full Text] [Related]
18. Immuno-regulatory antibodies for the treatment of cancer.
Honeychurch J; Cheadle EJ; Dovedi SJ; Illidge TM
Expert Opin Biol Ther; 2015 Jun; 15(6):787-801. PubMed ID: 25882106
[TBL] [Abstract][Full Text] [Related]
19. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L; Mills KHG
Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]